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Abstract
Background: Severe haemorrhage is a leading cause of maternal death worldwide. Most haemorrhage deaths
occur soon after childbirth. Severe post-partum bleeding is sometimes managed by the surgical removal of the
uterus (hysterectomy). Death and hysterectomy are important health consequences of post-partum haemorrhage,
and clinical trials of interventions aimed at preventing these outcomes are needed.
Methods: The World Maternal Antifibrinolytic trial aims to determine the effect of tranexamic acid on death,
hysterectomy and other health outcomes in women with post-partum haemorrhage. It is an international,
multicentre, randomised trial. Approximately 20,000 women with post-partum haemorrhage will be randomly
allocated to receive an intravenous injection of either tranexamic acid or matching placebo in addition to usual
care. The primary outcome measure is a composite of death in hospital or hysterectomy within 42 days of delivery.
The cause of death will be described. Secondary outcomes include death, death due to bleeding, hysterectomy,
thromboembolic events, blood transfusion, surgical and radiological interventions, complications, adverse events
and quality of life. The health status and occurrence of thromboembolic events in breastfed babies will also be
reported. We will conduct subgroup analyses for the primary outcome by time to treatment, type of delivery and
cause of haemorrhage. We will conduct an analysis of treatment effect adjusted for baseline risk.
Discussion: The World Maternal Antifibrinolytic trial should provide reliable evidence for the efficacy of tranexamic
acid in the prevention of death, hysterectomy and other outcomes that are important to patients. We present a
protocol update and the statistical analysis plan for the trial.
Trial registration: Current Controlled Trials ISRCTN76912190 (Registration date 08 December 2008), Clinicaltrials.gov
NCT00872469 (Registration date 30 March 2009) and Pan African Clinical Trials Registry: PACTR201007000192283
(Registration date 02 September 2010).
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Introduction
Severe haemorrhage is associated with approximately one-
quarter of maternal deaths worldwide [1]. Most of these
deaths occur soon after childbirth. Other leading causes of
maternal death are pre-existing medical conditions, high
blood pressure and sepsis [2]. Severe post-partum bleeding
is sometimes managed by the surgical removal of the uterus
(hysterectomy). As well as the morbidity from the surgery,
hysterectomy can cause psychological distress, particularly
in women who want to have more children [3]. Death and
hysterectomy are important health consequences of post-
partum haemorrhage (PPH), and clinical trials of interven-
tions aimed at preventing these outcomes are needed.
Tranexamic acid (TXA) reduces bleeding by inhibiting
the enzymatic breakdown of the blood-clotting proteins
fibrinogen and fibrin. A systematic review of clinical tri-
als of TXA in surgery showed that TXA reduces blood
loss by approximately one-third [4]. TXA also reduces
mortality in bleeding trauma patients. When given soon
after injury, TXA reduces the risk of death due to bleed-
ing by approximately one-third [5, 6]. A randomised,
controlled, open-label trial of TXA in women with PPH
showed that TXA reduced blood loss but recommended
that a larger international study is needed to investigate
whether TA can decrease the need for invasive proce-
dures and reduce maternal morbidity in women with
PPH [7]. Also, a systematic review of TXA for the pre-
vention and treatment of PPH concluded that insuffi-
cient evidence exists to support its use [8]. Taken
together, reason exists to believe that TXA might reduce
deaths due to bleeding following childbirth.
The World Maternal Antifibrinolytic (WOMAN) trial
aims to determine the effect of TXA on death, hysterec-
tomy and other health outcomes in women with post-
partum haemorrhage. The trial protocol was published
before the start of the trial [9]. The planned sample size
was increased from 15,000 to 20,000 participants in May
2014. This paper gives the reason for this increase and
presents the statistical analysis plan. Recruitment of
20,000 women should be complete by the summer of
2016. The statistical analysis plan was completed before
the treatment allocation was un-blinded.
Methods
Study design and patients
The WOMAN trial is an international, multicentre, ran-
domised, placebo-controlled trial. Adult women with
post-partum haemorrhage following vaginal or caesarean
section delivery who have a clinical diagnosis of post-
partum haemorrhage are eligible for enrolment. The
clinical diagnosis of PPH may be based on blood loss of
over 500 mL after vaginal delivery or 1,000 mL after cae-
sarean section or blood loss sufficient to compromise
the haemodynamic stability. The fundamental eligibility
criterion is the responsible clinician’s ‘uncertainty’ as to
whether or not to use TXA in a particular woman with
post-partum haemorrhage. Where TXA is indicated or
was administered, or where it is contra-indicated, pa-
tients are not included in the trial. No pre-specified ex-
clusion criteria exist. Patients receive all routine
clinically indicated medical care and additionally are ran-
domised to receive TXA or placebo. Hospitals where
TXA is in routine use for PPH are not included in the
trial. As the eligibility criteria automatically excluded pa-
tients who had received TXA, specific data on whether
it was used before enrolment was not collected.
Randomisation and masking
Randomisation codes were generated and secured by an
independent statistical consultant from Sealed Envelope
Ltd (London, UK). Trial treatment packs are prepared in
accordance with the randomisation list. Women eligible
for inclusion are randomised to receive either active
(TXA) or placebo (sodium chloride 0.9 %) intravenously.
Baseline information is collected on the trial entry form,
and the next lowest consecutively numbered pack is
taken from a box of eight treatment packs. Once the
treatment ampoule is confirmed as intact, the patient is
considered to be randomised. Once a patient has been
randomised, the outcome for the woman is obtained
even if the trial treatment is interrupted or not given.
Both participants and study staff (site investigators
and trial coordinating centre staff ) are masked to
treatment allocation. An emergency un-blinding ser-
vice is available.
Trial procedures
After eligibility is confirmed and the appropriate consent
procedure followed, each patient is assigned a uniquely
numbered treatment pack. In this way they are randomly
allocated to receive 1 gram of TXA or placebo by intra-
venous injection. If bleeding continues after 30 minutes,
or if bleeding stops and restarts within 24 h, a second
dose of 1 g of TXA or placebo may be given. No pre-
established maximum time between the start of PPH
and administration of the study treatment exists. After a
patient has been randomised, the outcome in hospital is
collected even if the trial treatment is interrupted or is
not actually given. Outcome is collected at 6 weeks
(42 days, as this usually defines the post-partum period)
after randomisation, at discharge from the randomising
hospital or at death (whichever occurs first). Adverse
events are reported in-hospital and after discharge up to
day 42.
Ethics approval
Before the trial can start at a site, all relevant regulatory
and ethics approvals are obtained. An additional file
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presents the current list of ethics approval for participat-
ing countries and sites (see Additional file 1).
Consent
The trial is being conducted in accordance with the
International Conference on Harmonisation of Tech-
nical Requirements for Registration of Pharmaceuticals
for Human Use–Good Clinical Practice (ICH-GCP), and
participant consent is obtained in accordance with the
approved protocol. The consent procedure used in the
WOMAN Trial is detailed in the published protocol [9].
The informed consent procedure used at each site is ap-
proved by the relevant ethics and regulatory agencies. In
summary, consent is obtained from patients if physical
and mental capacity allows consent. If a patient cannot
give consent, proxy consent is obtained from a relative
or representative. If a proxy was unavailable, then if per-
mitted by local regulation, consent is deferred or waived.
When consent is deferred or given by a proxy, the patient
is informed about the trial as soon as possible, and con-
sent obtained for use of the data collected, if needed.
Sample size
Before the trial started, we anticipated a baseline event
rate of 2.5 % for death and 2.5 % for hysterectomy. As-
suming a control group event rate of 2.5 % for death and
2.5 % for hysterectomy and that 1 % of women die after
hysterectomy, a study with 15,000 women should have
more than 90 % power to detect a 25 % reduction from
4 % to 3 % in the primary endpoint of death or hysterec-
tomy at the 5 % significance level. Expected loss to
follow-up (less than 1 %) should not impact importantly
on the power (at the time of writing this Statistical
Analysis Plan, we had achieved 99 % follow-up at 42 days
after randomisation, at discharge from hospital or death).
However, because the case fatality observed in the trial
(by December 2013) was higher (3 %) than expected, a
modest increase in the sample size from 15,000 to 20,000
women would mean that the trial may have sufficient
(90 %) power to detect a 25 % reduction in maternal mortal-
ity alone at the 5 % significance level. This increase also pro-
vided additional power to detect an effect on the composite
endpoint of death or hysterectomy, whilst providing protec-
tion against the possibility that the effect of TXA on death
and hysterectomy is different. Increasing the sample size to
20,000 women involved an extra 15 months of recruitment.
The primary outcome remains the same (i.e. a com-
posite of death and hysterectomy) with death alone as a
secondary outcome. The independent Data Monitoring
Committee was aware of the higher case fatality, as these
data were presented as part of their routine review. The
independent Trial Steering Committee also reviewed
and approved the sample size increase.
Statistical analysis
Trial profile
The flow of study participants will be displayed in a
CONSORT diagram [10], as shown in Fig. 1. Because
Fig. 1 Trial profile. †No follow-up relates to those patients where there is no information on the primary endpoint
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the trial involves a life-threatening emergency situation,
we did not require clinicians to complete a screening
log. The number of patients included in the primary and
secondary analyses, the reasons for exclusions and the
number of patients lost to follow-up will be reported.
Patients randomised who did not fulfil the eligibility
criteria and those who did not receive their allocated
treatment will be considered as having deviated from the
protocol. Their data will be included in the intention-to-
treat (ITT) analysis. If a patient or their representative
withdraws consent for data collection, only data up to
the point of withdrawal will be used in the analysis. Add-
itionally, we will summarise the type of consent process
used (number and percentage): patient, personal repre-
sentative, professional representative and waiver.
Planned analysis
Primary analysis
The main analyses will compare all those allocated
tranexamic acid versus those allocated placebo, on an
‘intention-to-treat’ basis, irrespective of whether they
received the allocated treatment or not.
Baseline characteristics
To check that randomisation produced broadly similar
groups, the baseline characteristics obtained prior to
randomisation will be presented as the number and per-
centage in each group (Table 1).
Primary outcome: death or hysterectomy
The primary outcome is a composite of death or hyster-
ectomy. Death and hysterectomy are important out-
comes for women, are easily measured and could
potentially be prevented by TXA. We use this composite
endpoint to increase the number of outcome events,
thereby increasing the statistical power to detect a treat-
ment effect [11]. Although the increase in power comes
at a cost of greater uncertainty in interpretation of the
results, the use of a composite endpoint is justified if the
components are of similar importance, occur with simi-
lar frequency and are likely to be affected to a similar
degree by the treatment [12, 13]. Whilst hysterectomy
cannot be considered as important as death, the com-
posite may be justified on the basis that hysterectomy is
conducted as a last resort to prevent death from bleed-
ing, in which case this less serious outcome may be a
reasonable surrogate for maternal death.
We anticipated that death and hysterectomy would
occur with similar frequency. Whether death and hys-
terectomy will be affected to a similar degree by TXA is
unknown, but to the extent that death and hysterec-
tomy are direct consequences of bleeding, we should
expect effects in the same direction, if not of a similar
magnitude.
During the trial, site monitoring showed that some
hysterectomies are conducted before randomisation.
For example, in response to the onset of severe life-
threatening bleeding during caesarean section, an
Table 1 Baseline characteristics of participants prior to
randomisation
Tranexamic
acid
Placebo
(n = 10,000) (n = 10,000)
Age at randomisation (years):
< 16 N (X %) N (X %)
16–25 N NNN (X %) N NNN (X %)
26–33 N NNN (X %) N NNN (X %)
34+ N NNN (X %) N NNN (X %)
Baby delivered in this hospital N NNN (X %) N NNN (X %)
Type of delivery:
Vaginal N NNN (X %) N NNN (X %)
Caesarean section N NNN (X %) N NNN (X %)
Time between delivery and
randomisation (hours):
≤ 1 N NNN (X %) N NNN (X %)
> 1 to ≤ 3 N NNN (X %) N NNN (X %)
> 3a N NNN (X %) N NNN (X %)
Placenta fully delivered:
Yes N NNN (X %) N NNN (X %)
No NNN (X %) NNN (X %)
Primary cause of haemorrhage:
Uterine atony N NNN (X %) N NNN (X %)
Placenta praevia/accreta N NNN (X %) N NNN (X %)
Surgical trauma/tears N NNN (X %) N NNN (X %)
Other N NNN (X %) N NNN (X %)
Unknown N NNN (X %) N NNN (X %)
Systolic BP (mmHg):
≥ 90 N NNN (X %) N NNN (X %)
< 90 N NNN (X %) N NNN (X %)
Estimated volume of blood lost (mL):
≤ 500 N NNN (X %) N NNN (X %)
> 500 to ≤ 1000 N NNN (X %) N NNN (X %)
> 1000 N NNN (X %) N NNN (X %)
Uterotonic prophylaxis given:
Yes N NNN (X %) N NNN (X %)
No N NNN (X %) N NNN (X %)
Not known N NNN (X %) N NNN (X %)
Clinical signs of haemodynamic instability:
Yes N NNN (X %) N NNN (X %)
No N NNN (X %) N NNN (X %)
aIncludes X patients randomly assigned more than 24 h after delivery
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obstetrician may decide to conduct a hysterectomy, and
while the hysterectomy is underway, the woman is en-
rolled into the trial. Similarly, in some cases of uterine
rupture, a hysterectomy is sometimes done prior to ran-
domisation. In other cases, a hysterectomy was conducted
in a peripheral hospital, and the woman is enrolled into
the WOMAN trial after having been transferred for the
management of ongoing bleeding. Although TXA might
reduce the risk of death in these cases, it could not affect
the risk of hysterectomy because the hysterectomy was
carried out prior to randomisation. Including such pa-
tients in the analysis will dilute the treatment effect to-
wards the null. Therefore, only hysterectomies carried out
after randomisation will be included. All hysterectomies
will be monitored before database lock using the Primary
Outcome Monitoring Form to confirm which ones were
done after randomisation (see Additional file 2).
Pearson’s chi-squared test will be used as the primary test
of statistical significance of the effect of treatment alloca-
tion on the composite of death or hysterectomy by 42 days.
Frequencies and percentages per arm, and the risk ratio for
the outcome with the treatment with its 95 % confidence
interval (CI) will be reported as shown in Table 2.
Imputation of missing data
As loss to follow-up is expected to be minimal (i.e. less
than 1 % missing data on the primary outcome), missing
values will not be imputed.
Subgroup analyses
All subgroups will be defined according to variables that
are measured before randomisation and will be pre-
sented as shown in Table 3. The following subgroup ana-
lyses will be carried out for the primary outcome (death
or hysterectomy), unless otherwise stated.
Time to treatment
The WOMAN trial was planned before the results of the
CRASH-2 trial of TXA in bleeding trauma patients were
available. The CRASH-2 trial, which recruited 20,210
adults with significant traumatic bleeding, showed that
TXA reduces death due to bleeding (RR = 0.85, 95 % CI
0.76–0.96) and all-cause mortality (RR = 0.91, 95 % CI
0.85–0.97), with no increase in vascular occlusive events.
The CRASH-2 trial investigators hypothesised that TXA
would be most effective when given soon after injury,
when bleeding is profuse, but less effective later, when
the acute phase response to trauma increases the risk
of thrombosis. They tested this hypothesis by conduct-
ing a pre-specified subgroup analysis of the effect of
TXA by time from injury to the start of treatment (≤ 1,
1– ≤ 3, 3–8 h) and found strong evidence in support of
their hypothesis (test of homogeneity p < 0.0001). In pa-
tients treated within 3 h of injury, TXA substantially re-
duced the risk of death due to bleeding, but when given
after 3 h, TXA appeared to increase the risk of death
due to bleeding [6].
Early activation of fibrinolysis is common after trauma
and is associated with increased mortality [14]. Tissue
plasminogen activator (TPA), the enzyme that converts
plasminogen to the active fibrinolytic enzyme plas-
min, is stored within the vascular endothelium in
secretory organelles called Weibel Palade bodies.
Trauma triggers the rapid release of tissue plasmino-
gen activator (TPA) from the vascular endothelium
resulting in fibrinolysis and increased bleeding [15].
By inhibiting early fibrinolysis, TXA reduces the risk
of exsanguination. The apparent increase in death
due to bleeding with late TXA administration may re-
flect PAI-1-induced suppression of fibrinolysis and
the onset of thrombotic disseminated intravascular
coagulation (DIC) [16]. The latter is characterised by
intravascular activation of coagulation with widespread
fibrin deposition. By inhibiting fibrinolysis, TXA could
worsen thrombotic DIC. Although the underlying
pathology is thrombotic, due to the consumption of
coagulation factors, thrombotic DIC usually manifests
as bleeding.
Table 2 Effect of tranexamic acid (TXA) on death or hysterectomy
TXA Placebo Risk ratio (95 % CI) p value*
(n = 10,000) (n = 10,000)
Death or hysterectomy NN (X %) NN (X %) X.XX (X.XX–X.XX) p = 0.XX
Death (all causes) NN (X %) NN (X %) X.XX (X.XX–X.XX) p = 0.XX
Bleeding deaths NN (X %) NN (X %) X.XX (X.XX–X.XX) p = 0.XX
Disseminated intravascular coagulation deaths NN (X %) NN (X %) X.XX (X.XX–X.XX) p = 0.XX
Pulmonary embolic deaths NN (X %) NN (X %) X.XX (X.XX–X.XX) p = 0.XX
Sepsis deaths NN (X %) NN (X %) X.XX (X.XX–X.XX) p = 0.XX
Deaths due to other causes NN (X %) NN (X %) X.XX (X.XX–X.XX) p = 0.XX
Hysterectomy NN (X %) NN (X %) X.XX (X.XX–X.XX) p = 0.XX
*p values from Pearson’s chi-squared test
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Similar temporal changes in fibrinolysis have been
observed after childbirth [17]. Within 1 h of delivery,
the serum concentration of TPA doubles, possibly due
to the trauma of childbirth. Thereafter, the TPA con-
centration falls steeply. On the other hand, levels of the
plasminogen activator inhibitors (PAI-1 and PAI-2) are
increased around the time of delivery and remain so for
several days. We might therefore expect TXA would be
most effective when given soon after delivery, when TPA
levels are highest, and less effective (possibly even harm-
ful) when given several hours after delivery, when the risk
of thrombotic DIC may be increased. We will examine
this hypothesis by conducting a sub-group analysis of the
effect of TXA according to the time interval between de-
livery and TXA treatment (≤1, > 1 to ≤ 3, > 3 h). The out-
come measure for this subgroup analysis will be death due
to bleeding. The results of this analysis will be considered
in the context of the relevant biological and clinical data
on the time to treatment interaction.
Type of delivery
Because a substantial proportion of all deliveries are by
caesarean section and caesarean section is an established
risk factor for post-partum haemorrhage [18], it is import-
ant to examine whether the effect of TXA on the risk of
death and hysterectomy varies by type of delivery. We do
not anticipate substantial heterogeneity by type of delivery.
Primary cause of post-partum haemorrhage
For post-partum haemorrhage due to uterine atony,
uterotonics are recommended as the first line treatment
[19]. It is believed that uterine contraction will compress
the spiral arteries and reduce bleeding. When planning the
WOMAN trial, some reviewers expressed concern that ad-
ministration of the WOMAN trial treatment might lead to
fewer women receiving prophylactic uterotonics. For this
reason, we collected information on uterotonic use and
planned a sub-group analysis on the basis of whether or not
uterotonics were administered. It was suggested that TXA
would be less effective in women who receive uterotonics,
particularly when uterine atony is the cause of bleeding.
However, because 99 % of women recruited to May 2014
received uterotonics, the planned subgroup analysis would
be uninformative. Instead, we will examine the effect of
TXA by cause of the bleeding (uterine atony versus all
other causes) as determined at baseline. We do not antici-
pate substantial heterogeneity by cause of haemorrhage.
The main analysis for the pre-specified subgroups will
be an unadjusted test of interaction in a logistic regression
model to assess evidence for whether the effect of treat-
ment differs across subgroup categories. Unless there is
strong evidence against the null hypothesis of homogen-
eity of effects (i.e. p < 0.001), the overall relative risk will
be considered the most reliable guide to the approximate
relative risks in all subgroups. For each subgroup, we will
report frequencies and percentages per arm with the RR
and 99 % CI as estimates of stratum-specific treatment ef-
fects, with the p value for the test of interaction.
Secondary outcomes
Death
Death will be analysed (separately from hysterectomy) as
a secondary outcome. As outlined above, although the
use of a composite endpoint increases the statistical power,
Table 3 Effect of tranexamic acid (TXA) on death or hysterectomy by subgroups
Subgroup TXA Placebo Risk ratio (99 % CI)
Death or hysterectomy Received TXA Death or hysterectomy Received Placebo
Time between delivery and randomisation:
≤ 1 h NN (X %) N NNN NN (X %) N NNN X.XX (X.XX–X.XX)
1–3 h NN (X %) N NNN NN (X %) N NNN X.XX (X.XX–X.XX)
> 3 h NN (X %) N NNN NN (X %) N NNN X.XX (X.XX–X.XX)
(p = 0.XXX)*
Type of delivery:
Vaginal NN (X %) N NNN NN (X %) N NNN X.XX (X.XX–X.XX)
Caesarean section NN (X %) N NNN NN (X %) N NNN X.XX (X.XX–X.XX)
(p = 0.XXX)
Primary cause of haemorrhage:
Uterine atony NN (X %) N NNN NN (X %) N NNN X.XX (X.XX–X.XX)
Other/unknown NN (X %) N NNN NN (X %) N NNN X.XX (X.XX–X.XX)
(p = 0.XXX)
Notes
*p values from unadjusted tests of interaction in a logistic regression model to assess evidence for whether the effect of treatment differs across
subgroup categories
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if the effect of TXA on death and hysterectomy are not
similar, it could make interpretation of the primary results
difficult. The causes of death will be analysed as shown in
Table 2. Also, there is no reason to believe that TXA can
prevent deaths from causes such as eclampsia or sepsis,
unless death from these other causes is made more likely
by bleeding. Therefore, we will assess the effect of TXA on
all-cause mortality and cause-specific mortality (death due
to bleeding, pulmonary embolism and other causes
(Table 2). We will present the distribution of causes of
death by days since randomisation as described in Fig. 2.
Thromboembolic events
An increased risk of venous thromboembolic events
(VTE) persists for several weeks post-partum [20]. Ven-
ous thrombosis is one of the leading causes of maternal
morbidity and mortality with about 95 % of these events
occurring during the first 4 weeks post-partum [21]. The
risk of deep vein thrombosis (DVT) is believed to be
higher than pulmonary embolism (PE) in the post-
partum period. Any further increase in risk from TXA
use would be important. We will therefore assess and
present the risk of venous (DVT and PE) and arterial
events (myocardial infarction (MI) and stroke) as shown
in Table 4. The definitions of DVT, PE, stroke and MI
used in the trial are shown in Additional file 3.
Surgical and radiological interventions to treat
haemorrhage
Hysterectomy will be analysed as a secondary outcome
(Table 2). Additionally, the following interventions will
be analysed: manual removal of the placenta, intrauterine
tamponade, embolisation, brace sutures of the uterus, arter-
ial ligation and laparotomy for other reasons (carried out
after randomisation to control bleeding and achieve haemo-
stasis for procedures other than those listed). If TXA reduces
bleeding, it may also reduce the need for these additional
treatments. However, as the decision to randomise can be
made at the same time, or even after these interventions
are carried out, some dilution of the treatment effect to-
wards the null might be expected. Surgical and radiological
events will be analysed in two ways: as individual events
and grouped as ‘surgical and radiological events’. These will
be summarised as the number and percentage of patients
per arm. These will be presented as shown in Table 4.
Blood transfusion
TXA has been shown to reduce the probability of receiv-
ing a blood transfusion by one-third in patients under-
going routine surgery [4]. If TXA can reduce the need
for blood product transfusion in women with PPH, this
would be an important finding. We will therefore assess
the effect of TXA on the use of whole blood or packed
red blood cells, fresh frozen plasma and other blood
products in transfusion. These will be summarised as the
number and percentage of patients per arm who receive
these, and the mean, (SD) or median (range) as appropri-
ate, units transfused per treatment arm. The effect of
treatment allocation will be tested using a two-sample t-
test (or Mann-Whitney rank sum test, as appropriate).
However, once again, since the decision to transfuse is
often made before or at the time of randomisation, some
dilution towards the null is to be expected. The results will
be presented as shown in Table 4.
Fig. 2 Distribution of cause of death by days since randomisation. Notes: Bars will be stacked to show number of deaths due to bleeding,
pulmonary embolism, or other causes.
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Quality of life
The impact on the quality of life of women who suffer
PPH is not well researched. One study suggests that the
health and quality of life of women after maternal mor-
bidities such as PPH, negatively affects the woman’s
wellbeing and quality of life [22]. Information on the
health status of women is collected on the outcome
form using the EQ-5D. This consists of two principal
measurement components. The first defines health-
related quality of life in terms of five dimensions:
Table 4 Effect of tranexamic acid (TXA) on thromboembolic events, need for surgery and transfusion and level of dependency
TXA Placebo Risk ratio (95 % CI) p value*
(n = 10,000) (n = 10,000)
Thromboembolic events
Any event NN (X %) NN (X %) X.XX (X.XX–X.XX) p = 0.XX
Venous events (DVT, PE) NN (X %) NN (X %) X.XX (X.XX–X.XX) p = 0.XX
DVT NN (X %) NN (X %) X.XX (X.XX–X.XX) p = 0.XX
PE NN (X %) NN (X %) X.XX (X.XX–X.XX) p = 0.XX
Arterial events (MI, stroke) NN (X %) NN (X %) X.XX (X.XX–X.XX) p = 0.XX
MI NN (X %) NN (X %) X.XX (X.XX–X.XX) p = 0.XX
Stroke NN (X %) NN (X %) X.XX (X.XX–X.XX) p = 0.XX
Surgical interventions
Hysterectomy NN (X %) NN (X %) X.XX (X.XX–X.XX) p = 0.XX
Manual removal of placenta NN (X %) NN (X %) X.XX (X.XX–X.XX) p = 0.XX
Intrauterine tamponade NN (X %) NN (X %) X.XX (X.XX–X.XX) p = 0.XX
Embolisation NN (X %) NN (X %) X.XX (X.XX–X.XX) p = 0.XX
Brace sutures of uterus NN (X %) NN (X %) X.XX (X.XX–X.XX) p = 0.XX
Arterial ligation NN (X %) NN (X %) X.XX (X.XX–X.XX) p = 0.XX
Laparotomy NN (X %) NN (X %) X.XX (X.XX–X.XX) p = 0.XX
Any surgical or radiological intervention NN (X %) NN (X %) X.XX (X.XX–X.XX) p = 0.XX
Blood transfusion
Whole blood NN (X %) NN (X %) X.XX (X.XX–X.XX) p = 0.XX
Packed red blood cells NN (X %) NN (X %) X.XX (X.XX–X.XX) p = 0.XX
Frozen plasma NN (X %) NN (X %) X.XX (X.XX–X.XX) p = 0.XX
Other blood products NN (X %) NN (X %) X.XX (X.XX–X.XX) p = 0.XX
Any transfusion NN (X %) NN (X %) X.XX (X.XX–X.XX) p = 0.XX
Blood transfusion (units)
Whole blood mean (SD) mean (SD) Diff in means (X.X – X.X) p = 0.XX
Packed red blood cells mean (SD) mean (SD) Diff in means (X.X – X.X) p = 0.XX
Frozen plasma mean (SD) mean (SD) Diff in means (X.X – X.X) p = 0.XX
Other blood products mean (SD) mean (SD) Diff in means (X.X – X.X) p = 0.XX
Any transfusion mean (SD) mean (SD) Diff in means (X.X – X.X) p = 0.XX
EQ-5Da
Mobility NN (X %) NN (X %) X.XX (X.XX–X.XX) p = 0.XX
Self-care NN (X %) NN (X %) X.XX (X.XX–X.XX) p = 0.XX
Usual activities NN (X %) NN (X %) X.XX (X.XX–X.XX) p = 0.XX
Pain/discomfort NN (X %) NN (X %) X.XX (X.XX–X.XX) p = 0.XX
Anxiety/depression NN (X %) NN (X %) X.XX (X.XX–X.XX) p = 0.XX
Visual analogue scale mean (SD) mean (SD) Diff in means (X.X – X.X) p = 0.XX
DVT deep vein thrombosis, MI myocardial infarction, PE pulmonary embolism
*p values from Pearson’s chi-squared test
aProportion with severe problems
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‘mobility’, ‘self-care’, ‘usual activities’, ‘pain/discomfort’ and
‘anxiety/depression’ [23]. Responses in each dimension are
divided into three ordinal levels, coded: (1) no problems,
(2) some or moderate problems and (3) severe or extreme
problems. The second measurement component of the
EQ-5D consists of a 20-cm vertical visual analogue scale
ranging from 100 (best imaginable health state) to 0
(worst imaginable health state), which provides an indica-
tion of the woman’s health status. EQ-5D Scores will be
presented as the proportions of women reporting prob-
lems (i.e. some, moderate, severe or extreme) on each EQ-
5D dimension. In addition, the means (with SD) of the
EQ-5D visual analogue scales per arm and the difference
in the means will also be reported in order to assess the
treatment effect, along with the p value from a two-
sample t-test. These will be presented as shown in Table 4.
Complications
Women with PPH are at risk of other significant medical
events associated with pregnancy and PPH. These in-
clude renal failure, cardiac failure, respiratory failure,
hepatic failure, sepsis and seizure, and these events are
collected routinely as outcomes. An increase in the risk
of seizure using high doses of TXA has been reported
[24, 25]. These will be presented as shown in Table 5.
Adverse events
Other untoward medical events are collected up to
42 days after randomisation as adverse events (AEs). In
line with ICH-GCP guidelines [26], an AE is considered
as serious if it results in death, is life-threatening, re-
quires inpatient hospitalisation or prolongation of exist-
ing hospitalisation, results in persistent or significant
disability/incapacity or results in a congenital anomaly/
birth defect. Where there is at least a possibility of an
adverse event being causally linked to the trial drug, this
is considered to be an adverse reaction. A suspected
unexpected serious adverse reaction (SUSAR) is an un-
expected occurrence of a serious adverse reaction. There
need only to be an index of suspicion that the event is a
previously unreported reaction to a trial drug or a
previously reported but exaggerated or unexpectedly fre-
quent adverse drug reaction.
The number of AEs, SAEs, and SUSARs grouped by
MedDRA® codes [27] and the number of patients with at
least one event will be compared between arms using a chi-
squared test (or Fisher’s exact test), with RRs and 95 % CI
when these are computable. Frequencies and percentages
per treatment group will be presented as shown in Table 6.
Status of babies
TXA is believed to pass into breast milk to a concentra-
tion of approximately one hundredth of the concentra-
tion in the maternal blood [28]. The number and
percentage of babies born alive per treatment group will
be described. Where babies were born alive and breast-
fed during the course of the follow-up period, their sta-
tus (alive or dead) will be presented as shown in Table 7.
Thromboembolic events in breastfed babies
Data on any thromboembolic events (TE) in babies are
collected. TE was defined as follows: the event must be a
confirmed diagnosis and may include any venous or ar-
terial thrombosis (thrombosis of limb artery/deep veins,
renal artery/veins, pulmonary embolism, hepatic veins,
caval veins, intracardiac thrombosis, portal vein, mesen-
teric veins/artery, cerebral veins, retinal vein, ischemic
stroke, arteries, aorta, myocardial infarction, microvascu-
lar thrombosis from purpura fulminans or disseminated
intravascular coagulation. These data will be presented
as shown in Table 7.
For all events reported in Tables 4, 5, 6 and 7, frequen-
cies and percentages per arm will be presented, with a
RR and 95 % CI as estimates of treatment effect, along
with the p value from Pearson’s chi-squared test.
Other analyses: to be reported in a separate
publication
Analysis 1: Adjusting for possible imbalance in baseline
prognostic factors
In a large trial such as the WOMAN trial, baseline char-
acteristics of patients that may influence the outcome
Table 5 Complications
Type of adverse
event
Tranexamic acid Placebo Risk ratio (95 % CI) p value*
(n = 10,000) (n = 10,000)
Renal failure N (X %) N (X %) X.XX (X.XX–X.XX) p = 0.XX
Cardiac failure N (X %) N (X %) X.XX (X.XX–X.XX) p = 0.XX
Respiratory failure N (X %) N (X %) X.XX (X.XX–X.XX) p = 0.XX
Hepatic failure N (X %) N (X %) X.XX (X.XX–X.XX) p = 0.XX
Sepsis N (X %) N (X %) X.XX (X.XX–X.XX) p = 0.XX
Seizure N (X %) N (X %) X.XX (X.XX–X.XX) p = 0.XX
Notes
*p values from Pearson’s chi-squared test
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should be evenly distributed between the treatment and
placebo groups, so that any difference in outcome can
be attributed to the intervention. However, it is still pos-
sible that a chance imbalance in important prognostic
factors could influence the results [29, 30]. To investi-
gate this possibility, we will conduct an analysis of the
effect of treatment that is adjusted for baseline risk. We
will build a prognostic model based on pre-specified
baseline variables and use it to estimate the predicted
risk of the outcome at baseline.
The primary outcome is death or hysterectomy; death
due to bleeding is an important secondary outcome. The
most important prognostic factors for these outcomes
that are measured at baseline are maternal age, esti-
mated blood loss, systolic blood pressure and haemo-
dynamic instability. These variables will be included in a
multivariable prognostic model based on the final trial
dataset. Although there are almost complete data on
these variables, in the case of missing data, the missing
values will be replaced by the mean of the observed data
[31].
The trial data will then be stratified into risk deciles as
shown in Tables 8 and 9 based on the predicted risk of
the outcomes at baseline. We will report frequencies and
percentages within each risk decile, and calculate a risk
ratio (with 95 % CI) for each risk decile. The pooled risk
ratio (with a 95 % CI) will be estimated as an inverse
variance weighted average of the stratum-specific risk ra-
tios. The pooled risk ratio should provide an estimate of
the treatment effect that is un-confounded by baseline
risk. The advantage of this approach is that the effect of
baseline risk on the treatment effect is more explicit
than when covariate-adjusted odds ratios are calculated
using logistic regression. Furthermore, risk ratios are
easier to interpret and apply to individual patients than
are odds ratios [32].
A forest plot will be prepared to show graphically how
the treatment effect varies by baseline risk. We will use a
chi-squared test to assess any heterogeneity in the treat-
ment effect across the risk groups, and we will calculate
the I-squared statistic to quantify the percentage of vari-
ability in effect estimates that is due to heterogeneity ra-
ther than chance. To reduce the likelihood of making
inappropriate inferences, we pre-specify that unless there
is strong evidence against the null hypothesis of homo-
geneity of effects (i.e. p < 0.001), the pooled relative risk
will be considered the most reliable guide to the ap-
proximate treatment effects in all risk strata. We do not
anticipate substantial heterogeneity by baseline risk.
However, we hypothesise that the risk reduction with
TXA would be greatest in patients at low risk of death
since a smaller proportion of these women will have un-
survivable bleeding.
Analysis 2: Cost-effectiveness
An economic analysis will be relevant if TXA clearly
demonstrates efficacy in achieving its clinical aims. In
this case, the study will be undertaken in the form of a
cost-effectiveness analysis with the aim of estimating the
incremental cost-effectiveness ratio comparing the use
of TXA with normal clinical practice. Analysis will be
based on adjusted life years gained. A further analysis
will explore the use of the EQ-5D data to quality-
adjusted survival. In this study, the economic analysis is
clearly bounded as virtually all significant resource use
will occur in the initial period of hospitalisation. As
such, neither a long-term resource analysis nor an ana-
lysis of out-of-hospital costs will be required. The trial
use of TXA is likely to mirror its use in normal clinical
practice, hence the cost-effectiveness estimated in the
trial (adjusted for protocol driven costs) will closely ap-
proximate cost-effectiveness in actual clinical practice.
Data on physical resource consumption (e.g. the length
and nature of hospital stay) will be collected for each pa-
tient and a common unit cost at a country level will be
Table 6 Adverse events
Type of adverse
eventa
Tranexamic acid Placebo Risk ratio
(95 % CI)
p value*
(n = 10,000) (n = 10,000)
MedDRA code groups N (X %) N (X %) X.XX (X.XX–X.XX) p = 0.XX
Notes
*p values from Pearson’s chi-squared test (or Fisher’s exact test)
aAE’s, SAE, and SUSAR grouped by MedDRA® codes
Table 7 Death or thromboembolic events in breast-fed babiesa
Tranexamic acid Placebo Risk ratio
(95 % CI)
p value*
(n = 10,000) (n = 10,000)
Any death (of breastfed baby) NN (X %) NN (X %) X.XX (X.XX–X.XX) p = 0.XX
Any thromboembolic event (of breastfed baby) NN (X %) NN (X %) X.XX (X.XX–X.XX) p = 0.XX
*p values from Pearson’s chi-squared test
aBabies born alive and breastfed for some duration
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applied. A sensitivity analysis will be undertaken to as-
sess the robustness of the economic analysis in response
to variations in key variables such as drug prices. In all
cases, the economic analysis will be integrated with the
clinical trial procedures to optimise efficiency and min-
imise inconvenience to patients.
Mechanical ventilation and intensive care unit (ICU)
admission are resource consumption measures and are
not required for all patients. Mechanical ventilation will
be summarised as number and percentage of patients
per arm who received such a therapy. Where mechanical
ventilation is used exclusively for general anaesthetic for
surgery, this data is excluded. Length of stay in the ICU
and the hospital will be censored due to early deaths or
by a stay in the ICU or hospital longer than 42 days.
Summary statistics will include the median and the
interquartile range computed separately for each treat-
ment arm.
Data monitoring and interim analyses
An independent Data Monitoring Committee (DMC)
is responsible for reviewing the progress of the trial,
including recruitment, data quality and main outcomes
and safety data. The DMC has the responsibility for
Table 8 Death or hysterectomy by predicted risk at baseline
Risk decilea Tranexamic acid (TXA) Placebo Risk ratio (95 % CI)
Death or hysterectomy Received TXA Death or hysterectomy Received placebo
1 NN (X %) N NNN NN (X %) N NNN X.XX (X.XX–X.XX)
2 NN (X %) N NNN NN (X %) N NNN X.XX (X.XX–X.XX)
3 NN (X %) N NNN NN (X %) N NNN X.XX (X.XX–X.XX)
4 NN (X %) N NNN NN (X %) N NNN X.XX (X.XX–X.XX)
5 NN (X %) N NNN NN (X %) N NNN X.XX (X.XX–X.XX)
6 NN (X %) N NNN NN (X %) N NNN X.XX (X.XX–X.XX)
7 NN (X %) N NNN NN (X %) N NNN X.XX (X.XX–X.XX)
8 NN (X %) N NNN NN (X %) N NNN X.XX (X.XX–X.XX)
9 NN (X %) N NNN NN (X %) N NNN X.XX (X.XX–X.XX)
10 NN (X %) N NNN NN (X %) N NNN X.XX (X.XX–X.XX)
Overall NN (X %) N NNN NN (X %) N NNN X.XX (X.XX–X.XX)
(I2 = X %, p = 0.XX)
Notes
aDeciles of the predicted risk of the outcome at baseline, using a prognostic model including the baseline variables maternal age, estimated blood loss, systolic
blood pressure and haemodynamic instability
Table 9 Death due to bleeding by predicted risk at baseline
Risk decilea Tranexamic acid (TXA) Placebo Risk ratio (95 % CI)
Death due to bleeding Received TXA Death due to bleeding Received placebo
1 NN (X %) N NNN NN (X %) N NNN X.XX (X.XX–X.XX)
2 NN (X %) N NNN NN (X %) N NNN X.XX (X.XX–X.XX)
3 NN (X %) N NNN NN (X %) N NNN X.XX (X.XX–X.XX)
4 NN (X %) N NNN NN (X %) N NNN X.XX (X.XX–X.XX)
5 NN (X %) N NNN NN (X %) N NNN X.XX (X.XX–X.XX)
6 NN (X %) N NNN NN (X %) N NNN X.XX (X.XX–X.XX)
7 NN (X %) N NNN NN (X %) N NNN X.XX (X.XX–X.XX)
8 NN (X %) N NNN NN (X %) N NNN X.XX (X.XX–X.XX)
9 NN (X %) N NNN NN (X %) N NNN X.XX (X.XX–X.XX)
10 NN (X %) N NNN NN (X %) N NNN X.XX (X.XX–X.XX)
Overall NN (X %) N NNN NN (X %) N NNN X.XX (X.XX–X.XX)
(I2 = X %, p = 0.XX)
Notes
aDeciles of the predicted risk of the outcome at baseline, using a prognostic model including the baseline variables maternal age, estimated blood loss, systolic
blood pressure and haemodynamic instability
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deciding whether, while randomisation is in progress, the
un-blinded results (or the un-blinded results for a particu-
lar subgroup), should be revealed to the TSC. They will do
this if, and only if, two conditions are satisfied: (1) the
results provide proof beyond reasonable doubt that
treatment is on balance either definitely harmful or
definitely favourable for all, or for a particular cat-
egory of, participants in terms of the major outcome,
and (2) the results, if revealed, would be expected to
substantially change the prescribing patterns of clini-
cians who are already familiar with other trial results
that exist. Exact criteria for ‘proof beyond reasonable
doubt’ are not, and cannot be, specified by a purely
mathematical stopping rule, but they are strongly in-
fluenced by such rules. This is in agreement with the
Haybittle-Peto stopping rule [33, 34], whereby an in-
terim analysis of major endpoint would generally need
to involve a difference between treatment and control
of at least three standard errors to justify premature
disclosure. An interim subgroup analysis would have
to be even more extreme to justify disclosure. This
rule has the advantage that the exact number and
timing of interim analyses need not be pre-specified.
In summary, the stopping rules require extreme dif-
ferences to justify premature disclosure and involve
an appropriate combination of mathematical stopping
rules and scientific judgment. To date, seven interim
analyses by the DMC have been conducted with no
recommendation for early stopping.
Data management and analysis software
The clinical database management system for WOMAN
Trial was built to comply with ICH-GCP and uses
MySQL and its accompanying manuals. PHP was used
to develop the dynamic web pages for user interface.
The database was developed by Sealed Envelope Ltd.
Data are collected at each participating site and trans-
mitted directly to the clinical trials unit (CTU) via the
database. Where there is poor internet connection, the
paper CRFs can be sent by fax or via email. Data checks
and cleaning are performed by the CTU. Data items to
be coded including Adverse Event term and terms used
to describe ‘other’ causes of death on the Outcome Form
are coded using MedDRA Version 12 [27]. The final
database lock will take place at the end of the trial
within 3 months from the time when the ‘last patient’ in
the ‘last follow-up’ has completed the trial. Data will be
exported for statistical analysis using the most recent
version of Stata (StataCorp LP, College Station, Texas,
USA).
Data sharing
Following publication of the primary and secondary ana-
lyses detailed in this statistical analysis plan, the trial
data will be made available via our data sharing portal -
The Free Bank of Injury and emergency Research Data
(freeBIRD) website (http://freebird.Lshtm.ac.uk). This
will allow for maximum utilisation of the data to im-
prove patient care and advance medical knowledge.
Discussion
This report presents and justifies the changes to our pre-
viously published protocol. The main changes are an in-
creased sample size from 15,000 patients to 20,000 and
changes to our planned subgroup analyses, time from
delivery to randomisation is a new subgroup, and the re-
moval of the subgroup ‘use of uterotonic prophylaxis’.
We have presented our plan for the statistical analyses
in advance of the database lock and un-blinding to guard
against data dependent analyses.
The WOMAN trial will provide reliable evidence for
the efficacy of tranexamic acid in the prevention of
death, hysterectomy and other outcomes important to
patients and clinicians. Aditional file 4 lists the collabor-
ating investigators who have participated in the
WOMAN Trial to date.
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